Influenza Clinical Trial
Official title:
Safety and Immunogenicity Among Adults of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines, 2013-2014 Formulations
The aim of the study is describe the safety and immunogenicity of Fluzone Quadrivalent and
Fluzone Intradermal vaccines in adults 18 to < 65 years of age, and to describe the safety
and immunogenicity of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults ≥ 65
years of age.
Primary Objective:
- To describe the safety of the 2013-2014 formulations of Fluzone Quadrivalent and
Fluzone Intradermal vaccines in adults 18 to < 65 years of age and the safety of the
2013-2014 formulations of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults
≥ 65 years of age.
Observational objectives:
- To describe the immunogenicity of the 2013-2014 formulations of Fluzone Quadrivalent
and Fluzone Intradermal vaccines in adults 18 to < 65 years of age and the
immunogenicity of the 2013-2014 formulations of Fluzone Quadrivalent and Fluzone
High-Dose vaccines in adults ≥ 65 years of age.
- To evaluate the compliance, in terms of immunogenicity, of each study vaccine (Fluzone
Quadrivalent, Fluzone Intradermal, and Fluzone High-Dose) in the applicable age group
with the historical requirements of the Committee for Human Medicinal Products (CHMP)
Note for Guidance (NfG) CPMP/BWP/214/96.
- To submit sera from selected subjects to the Center for Biologics Evaluation and
Research (CBER) for further analysis by the World Health Organization (WHO), the
Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration
(FDA) to support formulation recommendations for subsequent influenza vaccines.
Participants 18 to < 65 years of age on enrollment will be randomized to receive either
Fluzone Quadrivalent or Fluzone Intradermal vaccine. Participants ≥ 65 years of age at
enrollment will be randomized to receive either Fluzone Quadrivalent or Fluzone High-Dose
vaccine.
Solicited adverse event (AE) information will be collected for 7 days after each
vaccination, unsolicited AE and Serious adverse event information will be collected from
Visit 1 to Visit 2. Total duration of participation in the study is approximately 21 days.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
| Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
| Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
| Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
| Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
| Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
| Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
| Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
| Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
| Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
| Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
| Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
| Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
| Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
| Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
| Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
| Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |